Table 1 Baseline characteristics of no surgery cohort and surgery cohort of AJCC 8th T4N0-3M0 EC patients
Variables | No surgery n = 1478 | Surgery n = 344 | SMD |
|---|---|---|---|
Year of diagnosis | 0.210 | ||
2004–2009 | 789 (53.4%) | 219 (63.7%) | |
2010–2015 | 689 (46.6%) | 125 (36.3%) | |
Age | 0.253 | ||
< 65 years old | 691 (46.8%) | 204 (59.3%) | |
> = 65 years old | 787 (53.2%) | 140 (40.7%) | |
Sex | 0.216 | ||
Male | 1104 (74.7%) | 287 (83.4%) | |
Female | 374 (25.3%) | 57 (16.6%) | |
Race | 0.367 | ||
White | 1057 (71.5%) | 293 (85.2%) | |
Black | 307 (20.8%) | 29 (8.4%) | |
Other/unknown | 114 (7.7%) | 22 (6.4%) | |
Primary site | 0.608 | ||
Upper third | 285 (19.3%) | 21 (6.1%) | |
Middle third | 302 (20.4%) | 45 (13.1%) | |
Lower third | 607 (41.1%) | 236 (68.6%) | |
Unknown | 284 (19.2%) | 42 (12.2%) | |
Histology | 0.679 | ||
Adenocarcinoma | 530 (35.9%) | 233 (67.7%) | |
Squamous cell carcinoma | 824 (55.8%) | 101 (29.4%) | |
Other | 124 (8.4%) | 10 (2.9%) | |
Differentiation | 0.265 | ||
Grade I | 53 (3.6%) | 19 (5.5%) | |
Grade II | 494 (33.4%) | 126 (36.6%) | |
Grade III/IV | 610 (41.3%) | 157 (45.6%) | |
Unknown | 321 (21.7%) | 42 (12.2%) | |
T stage | 0.431 | ||
T4a | 318 (21.5%) | 97 (28.2%) | |
T4b | 438 (29.6%) | 43 (12.5%) | |
T4, NOS | 722 (48.8%) | 204 (59.3%) | |
N stage | 0.568 | ||
N0 | 669 (45.3%) | 115 (33.4%) | |
N1 | 345 (23.3%) | 109 (31.7%) | |
N2 | 72 (4.9%) | 44 (12.8%) | |
N3 | 30 (2.0%) | 32 (9.3%) | |
N1–3, NOS | 362 (24.5%) | 44 (12.8%) | |
Neoadjuvant therapy | |||
No | – | 110 (32.0%) | |
Yes | – | 234 (68.0%) | |
Regional nodes examined | |||
< 15 | – | 216 (62.8%) | |
> = 15 | – | 126 (36.6%) | |
Unknown | – | 2 (0.6%) | |
Radiotherapy | 0.316 | ||
No/unknown | 541 (36.6%) | 77 (22.4%) | |
Yes | 937 (63.4%) | 267 (77.6%) | |
Chemotherapy | 0.498 | ||
No/unknown | 569 (38.5%) | 58 (16.9%) | |
Yes | 909 (61.5%) | 286 (83.1%) | |